Replies to post #414609 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

Could, then, Simufilam compete with blarcamesine and Anavex? Could this proposed SAVA drug match or beat blarcamesine in the treatment of Alzheimer's?

It sure could. SAVA has been brave enough to include moderate AD patients in its trials whereas AVXL included more healthy patients. When you strip out the moderate patients, SAVA's results with mild patients are comparable to AVXL's with no negative side effects. The big hanging question about Simufilam is duration of efficiency and whether it can extend out past one year.